ADVERSE REACTIONS LIALDA tablets have been evaluated in 655 ulcerative colitis patients in controlled and open-label trials. In two 8-week placebo-controlled clinical trials involving 535 ulcerative colitis patients, 356 received 2.4g/day or 4.8g/day LIALDA tablets and 179 received placebo. More treatment emergent adverse events occurred in the placebo group (119) than in each of the [...]
Continue reading " LIALDA (mesalamine) Delayed Release Tablets part 2 "
INDICATIONS AND USAGE LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks has not been established. CONTRAINDICATIONS LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. PRECAUTIONS General: [...]
Continue reading " LIALDA (mesalamine) Delayed Release Tablets "
Imagine that a health care practitioner is about to begin an encounter with a patient. The practitioner accesses a list of current complaints along with the patient’s electronic health record. Much of that record was acquired and encoded by intelligent interviewing software prior to the patient’s visit.
Speaker: Massimo D’Amato, MD, Senior Investigator, Clinical Pharmacology, Rotta Research Laboratories, Monza, Italy The cholecystokinin (CCK) receptor antagonist dexloxiglu-mide (Rotta Research Laboratories/Forest Laboratories) might be a novel therapeutic agent for the treatment of constipation-predominant irritable bowel syndrome (C-IBS) in female patients, having demonstrated its effectiveness in relieving IBS symptoms, and because it is well-tolerated.
Novel Proton Pump Inhibitor for GERD with EE Speaker: Donald O. Castell, MD, Professor of Medicine, Medical University of South Carolina, Charleston, South Carolina Esomeprazole (Nexium generic, AstraZeneca), the S-isomer of generic omeprazole, when taken in doses of 40 mg daily, is more effective in rapidly achieving sustained resolution of daily and nocturnal heartburn in [...]
Problem: Many medication errors are hard to detect, but some that occur during the prescribing phase can be especially elusive and can lead to controversy as to whether they are truly errors or acceptable differences in professional judgement. For example, when a nurse fails to administer a drug as prescribed or a pharmacist fails to [...]
Continue reading " Medication Error or Professional Judgement "
Another important factor to consider when collecting data for an outcomes management program is data error. The traditional approach can be associated with poor data quality because respondents might unintentionally skip questions and provide multiple responses to single survey items. Compared to the traditional method for SF-36 administration, the fax-based approach obviates the need for [...]
